{"DataElement":{"publicId":"2532940","version":"1","preferredName":"Chemotherapy Regimen Anthracycline Inclusion Code","preferredDefinition":"Numeric code to denote that a treatment regimen includes anthracyclines for the treatment of disease.","longName":"CHEMO_ANTHR_INCL_CD","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2532936","version":"1","preferredName":"Chemotherapy Regimen Inclusion Anthracycline","preferredDefinition":"A treatment plan using synthetic or naturally-occurring chemicals that includes anthraclines for the treatment of disease.","longName":"CHEMO_RGM_ANTHR_INCL","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2533629","version":"1","preferredName":"Chemotherapy Regimen","preferredDefinition":"Drug therapy using two or more drugs given together or separately for a combined effect.","longName":"C12218","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy Regimen or Agent Combination","conceptCode":"C12218","definition":"A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"211C91A8-CCA9-53E5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-31","modifiedBy":"ONEDATA","dateModified":"2006-10-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2532934","version":"1","preferredName":"Inclusion Anthracycline Antibiotic","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:A member of a family of anticancer drugs that are also antibiotics.","longName":"C25532:C1594","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anthracycline Antineoplastic Antibiotic","conceptCode":"C1594","definition":"An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20F9B18C-326C-2EA6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"ONEDATA","dateModified":"2006-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20F9B18C-327D-2EA6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2532938","version":"1","preferredName":"Anthracycline Inclusion Code","preferredDefinition":"System of numeric values to denote the inclusion of anthracycline agents in a regimen.","longName":"ANTHR_INCL_CD","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":"Chemo/Anthracycline (regimen or single agent)","ValueMeaning":{"publicId":"2581427","version":"1","preferredName":"Chemo/Anthracycline (regimen or single agent)","longName":"2581427","preferredDefinition":"Chemo/Anthracycline (regimen or single agent)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0B20-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"REEVESD","dateModified":"2006-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"20F9C428-087F-310E-E044-0003BA3F9857","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"REEVESD","dateModified":"2006-10-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Chemo/non-Anthracycline (regimen or single agent)","ValueMeaning":{"publicId":"2581428","version":"1","preferredName":"Chemo/non-Anthracycline (regimen or single agent)","longName":"2581428","preferredDefinition":"Chemo/non-Anthracycline (regimen or single agent)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0B21-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"REEVESD","dateModified":"2006-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"20F9C428-088B-310E-E044-0003BA3F9857","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"REEVESD","dateModified":"2006-10-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2532937","version":"1","preferredName":"Anthracycline Antibiotic Inclusion Code","preferredDefinition":"A member of a family of anticancer drugs that are also antibiotics.:The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:A system of numbered categories for representation of data.","longName":"C1594:C25532:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anthracycline Antineoplastic Antibiotic","conceptCode":"C1594","definition":"An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20F9B18C-32A5-2EA6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"ONEDATA","dateModified":"2006-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20F9B18C-32B6-2EA6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812723","version":"1","longName":"ThermoDox Study","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"Therapy Code","type":"Preferred Question Text","description":"Therapy Code","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"20F9D126-BD9B-320A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-29","modifiedBy":"LUY","dateModified":"2013-09-13","changeDescription":"Curated to support Duke University adoption of C3D for ThermoDox trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}